Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;255(4):817-824.
doi: 10.1007/s00417-017-3590-4. Epub 2017 Jan 27.

Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration

Affiliations
Free article

Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration

Rafidah Saleh et al. Graefes Arch Clin Exp Ophthalmol. 2017 Apr.
Free article

Abstract

Purpose: The purpose was to evaluate the effects of long-term anti-VEGF treatment on the retinal nerve fiber layer (RNFL) and retinal ganglion cell layer (RGCL) thickness for patients with neovascular AMD and glaucoma.

Methods: Medical records of respective patients who had received more than 15 anti-VEGF injections were reviewed. Initial and latest SD-OCT macular scans were segmented and changes of the RNFL and RGCL thickness at the four outer ETDRS quadrants were evaluated. Secondary outcome measures included changes of visual field parameters seen in automated perimetry.

Results: Sixteen patients were included (mean age 78 ± 6 years). The mean total number of anti-VEGF injections was 39 ± 16. The mean treatment duration was 6.1 ± 2.1 years. The mean IOP decreased from 18 ± 5 mmHg at baseline to 15 ± 5 mmHg at the last visit (p = 0.026). The mean RNFL thickness volume of the outer ETDRS quadrants (0.98 ± 0.18 mm3 to 0.97 ± 0.18 mm3 p = 0.61) and its average thickness (37.9 ± 7.3 μm to 37.2 ± 7.4 μm, p = 0.6) did not significantly change. However, the average RGCL thickness decreased significantly from 0.86 ± 0.12 mm3 to 0.79 ± 0.11 mm3 (p = 0.01), and from 27.7 ± 4.2 to 25.9 ± 3.7 μm (p = 0.01). Number of injections correlated with the RGCL change (r2 = 0.36, p = 0.01). The mean sensitivity, mean defect and absolute scotomata did not significantly change with p-values of 0.28, 0.21 and 0.07, respectively.

Conclusion: Patients under long term treatment with anti-VEGF and concurrent glaucoma show significant decrease in macular RGLC volume. However, this decrease is comparable to reported RGCL decrease in patients under anti-VEGF treatment without underlying glaucoma and suggests that glaucoma patients may not be at a higher risk for losing macular RNFL and RGCL, at least if adequate control of intraocular pressure is maintained.

Keywords: Anti-VEGF; Exudative age-related macular degeneration; Ganglion cell layer thickness; Glaucoma; Intraocular pressure; Ocular hypertension; Retinal layer segmentation; Retinal nerve fiber layer thickness; Visual fields; Wet AMD.

PubMed Disclaimer

References

    1. Arch Ophthalmol. 1991 Jan;109(1):77-83 - PubMed
    1. Am J Ophthalmol. 2008 Dec;146(6):930-4.e1 - PubMed
    1. Ophthalmology. 2009 Dec;116(12):2305-14.e1-2 - PubMed
    1. Retina. 2015 Aug;35(8):1489-506 - PubMed
    1. Am J Ophthalmol. 2015 Aug;160(2):283-289.e1 - PubMed

MeSH terms

Substances